File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors

TitleAdjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors
Authors
Issue Date2017
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
Hong Kong Medical Journal, 2017, v. 23 n. 1, p. 54-62 How to Cite?
AbstractIntroduction: The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. There are limited data on the tolerability of S-1 in Chinese patients. In this multicentre retrospective study, we assessed the toxicity profile in local patients. Methods: Patients with stage II-IIIC gastric adenocarcinoma who had undergone curative resection and who had received S-1 adjuvant chemotherapy were included in the study. Patient demographics, tumour characteristics, chemotherapy records, as well as biochemical, haematological, and other toxicity profiles were extracted from medical charts. Potential factors associated with grade 2-4 toxicities were identified. Results: Adjuvant S-1 was administered to 30 patients. Overall, 19 (63%) patients completed eight cycles. The most common grade 3-4 adverse events included neutropaenia (10%), anaemia (6.7%), septic episode (16.7%), diarrhoea (6.7%), hyperbilirubinaemia (6.7%), and syncope (6.7%). Dose reductions were made in 22 (73.3%) patients and 12 (40.0%) patients had dose delays. Univariate analyses showed that patients who underwent total gastrectomy were more likely to experience adverse haematological events (P=0.034). Patients with nodal involvement were more likely to report adverse non-haematological events (P=0.031). Patients with a history of regular alcohol intake were more likely to have earlier treatment withdrawal (P=0.044). Lower body weight (P=0.007) and lower body surface area (P=0.017) were associated with dose interruptions. Conclusions: The tolerability of adjuvant S-1 in our patient population was similar to that in other Asian patient populations. The awareness of S-1–related toxicities and increasing knowledge of potential associated factors may enable optimisation of S-1 therapy.
Persistent Identifierhttp://hdl.handle.net/10722/229160
ISSN
2019 Impact Factor: 1.679
2015 SCImago Journal Rankings: 0.279
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeo, W-
dc.contributor.authorLam, KO-
dc.contributor.authorLaw, LYA-
dc.contributor.authorLee, CCY-
dc.contributor.authorChiang, CL-
dc.contributor.authorAu, KH-
dc.contributor.authorMo, KF-
dc.contributor.authorSo, TH-
dc.contributor.authorLam, KC-
dc.contributor.authorNg, WT-
dc.contributor.authorLi, L-
dc.date.accessioned2016-08-23T14:09:21Z-
dc.date.available2016-08-23T14:09:21Z-
dc.date.issued2017-
dc.identifier.citationHong Kong Medical Journal, 2017, v. 23 n. 1, p. 54-62-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/229160-
dc.description.abstractIntroduction: The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. There are limited data on the tolerability of S-1 in Chinese patients. In this multicentre retrospective study, we assessed the toxicity profile in local patients. Methods: Patients with stage II-IIIC gastric adenocarcinoma who had undergone curative resection and who had received S-1 adjuvant chemotherapy were included in the study. Patient demographics, tumour characteristics, chemotherapy records, as well as biochemical, haematological, and other toxicity profiles were extracted from medical charts. Potential factors associated with grade 2-4 toxicities were identified. Results: Adjuvant S-1 was administered to 30 patients. Overall, 19 (63%) patients completed eight cycles. The most common grade 3-4 adverse events included neutropaenia (10%), anaemia (6.7%), septic episode (16.7%), diarrhoea (6.7%), hyperbilirubinaemia (6.7%), and syncope (6.7%). Dose reductions were made in 22 (73.3%) patients and 12 (40.0%) patients had dose delays. Univariate analyses showed that patients who underwent total gastrectomy were more likely to experience adverse haematological events (P=0.034). Patients with nodal involvement were more likely to report adverse non-haematological events (P=0.031). Patients with a history of regular alcohol intake were more likely to have earlier treatment withdrawal (P=0.044). Lower body weight (P=0.007) and lower body surface area (P=0.017) were associated with dose interruptions. Conclusions: The tolerability of adjuvant S-1 in our patient population was similar to that in other Asian patient populations. The awareness of S-1–related toxicities and increasing knowledge of potential associated factors may enable optimisation of S-1 therapy.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleAdjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors-
dc.typeArticle-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailLaw, LYA: lawlya@hku.hk-
dc.identifier.emailLee, CCY: lcy4591@hkucc.hku.hk-
dc.identifier.emailSo, TH: sth495@hku.hk-
dc.identifier.emailNg, WT: ngwt1@hkucc.hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authoritySo, TH=rp01981-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.12809/hkmj164885-
dc.identifier.pmid27966431-
dc.identifier.scopuseid_2-s2.0-85012034477-
dc.identifier.hkuros260819-
dc.identifier.volume23-
dc.identifier.issue1-
dc.identifier.spage54-
dc.identifier.epage62-
dc.identifier.isiWOS:000394405700009-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats